Journal
PHARMACY WORLD & SCIENCE
Volume 29, Issue 3, Pages 126-130Publisher
SPRINGER
DOI: 10.1007/s11096-006-9063-1
Keywords
anticholinergics; antipsychotic agents; drug therapy combination; drug use study; Europe; pharmaco-epidemiology; polypharmacy
Categories
Ask authors/readers for more resources
Objective The aim of this study was to investigate to what extent atypical antipsychotics, conventional antipsychotics and anticholinergics are prescribed simultaneously in daily clinical practice in Europe. Method A pharmaco-epidemiological study was carried out in which hospital pharmacists from 45 hospitals in Belgium, Denmark, France, Germany, The Netherlands and Scotland participated. Prescription data for 2,725 patients (mainly inpatients) who had been using an atypical antipsychotic for more than 6 weeks were analysed. Main outcome measure The frequencies of simultaneous prescription of atypical antipsychotics with other antipsychotics and/or anticholinergics. Results In this sample of patients with an atypical antipsychotic 42.1% was prescribed another antipsychotic (24.1% if low-potent antipsychotics were not included in the analysis) and 30.1% was prescribed an anticholinergic. In total 47.1% of patients were prescribed an atypical antipsychotic without any other antipsychotic or anticholinergic. Conclusion It is common practice to prescribe a combination of atypical antipsychotics and conventional antipsychotics and/or anticholinergics. This suggests that monotherapy involving an atypical antipsychotic is not considered to be an adequate treatment for a substantial number of patients in clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available